tirzepatide vs semaglutide comparison weight loss efficacy side effects caused roughly half as many patients to stop treatment because of gastrointestinal as semaglutide. In the first major head-to-head obesity trial, GI side effects caused treatment discontinuation in: Tirzepatide Tirzepatide vs. Semaglutide for Weight

Wegovy and its GLP-1 siblings, then, run the risk of being the holy grail that remains just beyond reach

This is desirable for wound healing but theoretically problematic for patients with active malignancies or a history of angiogenesis-dependent tumors

This involves taking a significantly smaller amount of the medication than the official 2.5mg (Mounjaro) or 0.25mg (Wegovy) starting doses, and is a method some propose to avoid side effects, cut costs, or try to maintain their target weight by using the smallest possible amount of the drug as a maintenance dose

Researchers have taken advantage of this process to produce RGD-modified complexes that can facilitate targeted anticancer drug delivery following receptor-mediated internalization